<DOC>
	<DOCNO>NCT01414114</DOCNO>
	<brief_summary>The purpose study evaluate effect thrice weekly intravenous ( IV ) administration KAI-4169 treatment secondary hyperparathyroidism ( SHPT ) hemodialysis subject chronic kidney disease-mineral bone disorder ( CKD-MBD ) .</brief_summary>
	<brief_title>Study KAI-4169 Treat Secondary Hyperparathyroidism Hemodialysis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Subjects provide write informed consent Screening intact PTH ( iPTH ) ≥350 pg/mL correct calcium ≥ 8.5 mg/dL Hemoglobin ≥ 8.5 g/dL Serum transaminase ( ALT SGPT , AST SGOT ) less 2.5 time upper limit normal Adequate hemodialysis three time per week History symptomatic ventricular dysrhythmias History angina pectoris congestive heart failure History myocardial infarction , coronary angioplasty , coronary artery bypass graft within past 6 month History treatment seizure disorder within last 12 month Postdialysis systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 90 mmHg Serum magnesium lower limit normal screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Clinical Trial , Phase 2</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Chronic kidney disease-mineral bone disorder</keyword>
	<keyword>Parathyroid hormone</keyword>
</DOC>